Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator committed to acquiring and developing early-stage technologies that seek to grow and push pharmacy forward. Since its inception, this Vancouver-based enterprise has stayed true to its mission to become the world’s largest health data company. This is evidenced by its move to innovate and leverage specific point-of-care technologies within its community of pharmacies.
Avricore’s flagship platform, HealthTab(TM), impacts the healthcare sector mainly by simplifying patients’ lives with easy access to point-of-care testing. With HealthTab, Avricore can offer pharmacies complete turnkey and point-of-care rapid testing systems covering both software and hardware (
https://ibn.fm/GN0Tk). Consequently, customers can quickly and conveniently check for markets associated with conditions such as heart disease, diabetes or any other conditions, with a simple finger-prick blood test and under the guidance of a pharmacist.
“HealthTab is a way for anybody to get access to important health information in a way that’s convenient for them, and at a time that’s convenient for them,” noted Rodger Seccombe, the Chief Technology Officer (“CTO”) at Avricore (
https://ibn.fm/fo4Sk).
It is one thing to have the technology and expertise to test patients quickly, but it is a whole other thing to get it to the intended patients. This is why Avricore has resorted to partnerships in a decentralization move that facilitates its growth and makes its technology and services accessible to as many people as possible.
So far in 2021, Avricore has secured a distribution agreement with Abbott Canada, the first of its type for a health-data company. Avricore also entered into a master agreement with Shoppers Drug Mart in Canada, giving its service access to over 1,300 stores, a move that so far is proving successful. With the point-of-care diagnostics market projected to grow to $50.6 billion by 2025, Avricore is positioning itself to grow with it and arguably become a leader in the industry (
https://ibn.fm/ySU2M).
Currently, Avricore earns its revenue from data collection, equipment leasing, API integration, the sale of consumables associated with testing, along with screening tests. As time progresses, and with the investments and partnerships it is forging along the way, the company looks forward to forming an in-pharmacy network. This would allow it to secure steady revenues and collect real-world data that would enable researchers to quickly and efficiently examine health data trends, eventually transforming that into another source of income.
The COVID-19 pandemic presented a massive growth for Avricore’s market opportunity. For starters, the public learned the positive impacts of early detection and rapid testing. Avricore’s Chief Executive Officer (“CEO”), Hector Bremner, acknowledged this opportunity, even citing rapid testing and early detection as “The future of pharmacy (
https://ibn.fm/DJtmQ).” With different companies also recognizing this opportunity, Avricore has managed to stay one step ahead by bringing its services closer to the people with its pharmacies.
“Yes, you need good instruments, but you need a whole system around that instrument,” noted Seccombe. “That’s where we’ve come in and developed a real out-of-box solution that works for pharmacies (
https://ibn.fm/DJtmQ).”
All the milestones achieved by Avricore throughout 2021, including the Ellerca Health Partnership, HealthTab rollout and the Shoppers Drug Mart agreement, among others, are representative of an enterprise that is constantly pushing the envelope in the healthcare sector. Avricore is staying true to its mission, and because of this, it is defining the future of healthcare.
To learn more about the company, please visit
www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at
https://ibn.fm/AVCRF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.